New findings may enhance PARP inhibitors therapy in breast cancer

Findings from a new study reveal that PARP inhibitors, an emerging class of drugs being studied in cancer clinical trials, may be enhanced by combining them with inhibitors targeting an oncogene known as c-MET which is overexpressed in many cancers.

The findings resulting from in vitro and mouse model studies were published in today's online issue of Nature Medicine. Study lead investigator Mien-Chie Hung, Ph.D., chair of Molecular and Cellular Oncology at The University of Texas MD Anderson Cancer Center, believes the study results may hold promise for future treatment of breast cancer and possibly other cancers.

"These findings may predict tumor resistance to PARP inhibitors and suggest that treatment with a combination of c-MET and PARP inhibitors may benefit patients bearing tumors with high c-MET expression who do not respond to PARP inhibition alone," said Hung.

While PARP inhibitors are still in the clinical trial phases for breast cancer, the FDA recently approved the PARP inhibitor olaparib for treatment of ovarian cancer with mutations in breast cancer genes known as BRCA.

"BRCA1 and BRCA2 play essential roles in repairing DNA double strand breaks and a deficiency of BRCA proteins sensitizes cancer cells to PARP inhibition," said Hung. "Combining c-MET and PARP1 inhibitors synergized to suppress growth of breast cancer cells. Similar synergistic effects were also observed in a lung cancer mouse model."

Hung's team discovered that c-MET associates with and phosphorylates PARP1, which increases its enzymatic activity. This process essentially renders cancer cells resistant to PARP inhibition. By blocking c-MET's cancer-friendly interaction with PARP, cancer cells lose this resistance to the therapy.

"Our study findings raise the interesting possibility that cancer patients with tumors that overexpress c-MET may benefit from this combination therapy regardless of cancer type," said Hung.

MD Anderson participants in the study included Yi Du, Ph.D., Hirohito Yamaguchi, D.V.M., Ph.D., Yongkun Wei, Ph.D., Jennifer Hsu, Ph.D., Yi-Hsin Hsu, Ph.D., Wan-Chi Lin, Ph.D., Wen-Hsuan Yu, Mei-Kuang Chen, Katsuya Nakai, M.D., Ph.D., Ming-Chuan Hsu, Ph.D., Ye Sun and Chun-Te Chen, Ph.D., all of Molecular and Cellular Oncology; Paul Leonard, Ph.D., and Gilbert Lee IV, Genomic Medicine; Philip Jones, Ph.D., Institute for Applied Cancer Science; Yun Wu, M.D., Ph.D., Pathology; and Gabriel Hortobagyi, M.D., Breast Medical Oncology.

Other participating institutions included China Medical University, Taichung, Taiwan; The University of Texas Graduate School of Biomedical Sciences, Houston; Academia Sinica, Taipei; Mackay Memorial Hospital, Taipei; McGill University, Montreal; and Asia University, Taichung, Taiwan.

The study was funded by the National Institutes of Health (CA109311, CA099031 and CA16672), the Susan G. Komen For the Cure (SAC100016), Breast Cancer Research Foundation, Patel Memorial Breast Cancer Endowment Fund, The University of Texas MD Anderson-China Medical University and Hospital Sister Institution Fund; Ministry of Science and Technology, International Research-Intensive Centers of Excellence in Taiwan (I-RiCE), MOST (104-2911-I-002-302), Ministry of Health and Welfare, China Medical University Hospital, and the Ting Tsung and Wei Fong Chao Research Fund.

Most Popular Now

Meditation, yoga and vegetarian diet linked to dec…

In a novel controlled clinical trial, participants in a six-day Ayurvedic-based well-being program that featured a vegetarian diet, meditation, yoga and massages experien...

Read more

Abbott to sell Abbott Medical Optics to Johnson …

Abbott (NYSE: ABT) announced today that it will sell Abbott Medical Optics, its vision care business, to Johnson & Johnson for $4.325 billion in cash. Abbott's vision bus...

Read more

Novartis convenes experts to discuss new technolog…

Novartis today opened the 13th International Biotechnology Leadership Camp (BioCamp). Over the course of three days more than 60 selected students from international univ...

Read more

Caffeine and its analogues revert memory deficits …

A study published in the journal Scientific Reports from Nature publishing group, describes the mechanism by which caffeine counteracts age-related cognitive deficits in ...

Read more

Amgen obtains global development and commercial ri…

Amgen (NASDAQ:AMGN) and Boehringer Ingelheim today announced that Amgen has acquired global development and commercial rights from Boehringer Ingelheim for BI 836908 (AMG...

Read more

Vitamin C may boost effectiveness of acute myeloid…

A simple adjustment to patients' therapeutic regimen may improve the effectiveness of the standard epigenetic treatment for myeloid dysplastic syndrome (MDS) and acute my...

Read more

Roche ranked most sustainable healthcare company i…

For the eighth consecutive year, Roche (SIX: RO, ROG; OTCQX: RHHBY) has been recognised as Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life...

Read more

10th European Medical Information and Communicatio…

29 - 30 November 2016, Berlin, Germany The 10th year of the Annual European Medical Information and Communications Conference is a unique meeting organised by medical in...

Read more

Saniona and Boehringer Ingelheim sign collaboratio…

Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies, and Saniona, a leading biotech company in the field of ion channel drug discovery, have ente...

Read more

Study shows how Chinese medicine kills cancer cell…

Researchers at the University of Adelaide have shown how a complex mix of plant compounds derived from ancient clinical practice in China - a Traditional Chinese Medicine...

Read more

Benralizumab phase III trials show positive result…

Results from pivotal Phase III trials presented at the European Respiratory Society (ERS) International Congress demonstrated that adding benralizumab to standard-of-care...

Read more

Antibody reduces harmful brain amyloid plaques in …

Although the causes of Alzheimer's disease are still unknown, it is clear that the disease commences with progressive amyloid deposition in the brains of affected persons...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]